Selective histone deacetylase inhibition as a therapeutically relevant strategy in H3K27M-glioma
Neuro-Oncology · 2026
DOI: 10.1093/neuonc/noag142 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neuro-Oncology, 2026. Verfasst von Andrew Groves und 24 weiteren Autor:innen. Beteiligte Einrichtung: Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Harvard Medical School, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Histone Deacetylase Inhibitors, Glioma, Brain Neoplasms, Histone Deacetylase 2. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Pediatric Brain Tumor Foundation, Musella Foundation for Brain Tumor Research & Information Inc., ChadTough Defeat DIPG Foundation.
Abstract (Originalsprache)
Background
Diffuse midline glioma (DMG) is a lethal pediatric brain tumor, driven by profound epigenetic dysregulation, raising the possibility that targeting epigenetic regulators such as histone deacetylases (HDACs) could provide a therapeutic benefit. However, despite preclinical activity, currently available HDAC inhibitors have shown limited clinical translation due to poor central nervous system (CNS) penetration and a lack of HDAC isoform selectivity.
Methods
We combined CRISPR/Cas9 screening and pharmacologic HDAC inhibition to identify isoform-specific dependencies in DMG cell lines. Mechanistic studies were performed using bulk RNA-seq and HiChIP, and therapeutic efficacy was evaluated in orthotopic patient-derived xenograft mouse models.
Results
We identify that the nuclear-localized Class I HDAC isoforms are dependencies in DMG and demonstrate that HDAC2 represents a selective dependency that is highly expressed in patient tumors. We further identify a CNS-penetrant HDAC inhibitor, Compound 26, with preferential HDAC1/2 isoform selectivity. Transcriptomic and chromatin conformation analyses reveal that Compound 26 induces rapid transcriptional reprogramming, restores physiologic pontine histone patterns, and induces cell cycle arrest through chromatin reorganization. Consistent with these effects, Compound 26 slows DMG growth in vitro and in orthotopic in vivo models.
Conclusions
Our findings establish HDAC2 as a critical and therapeutically actionable dependency in DMG. Genetic or pharmacological targeting of HDAC2 disrupts DMG chromatin architecture and induces cell cycle arrest. The HDAC1/2-selective inhibitor Compound 26 exhibits favorable CNS-penetration, tolerability, and antitumor activity in disease-relevant patient-derived xenograft models. Collectively, these data support isoform-selective HDAC inhibition as a rational strategy to overcome the translational limitations of pan-HDAC inhibitors in DMG.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Harvard Medical School, Boston, Massachusetts, USA.
- Broad Institute of Harvard and MIT, Cambridge, Massachusetts, USA.
- Division of Hematology/Oncology, University of Iowa Stead Family Children's Hospital, Iowa City, Iowa, USA.
- Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
- Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA.
- Department of Chemistry & Chemical Biology, Harvard University, Cambridge, Massachusetts, USA.
ORCID-Profile: Andrew Groves, Orville O Kirkland, Costanza Lo Cascio, Xiuqi Wang, Caleb Heaslip, Joana Graca Marques, Tingjian Wang, Diana H Chin, Yaw Asante, Qi Liu, Hyunmin Kim, Maria Trissal, Jenna Labelle, Gustavo Alencastro Veiga Cruzeiro, Amy B Cameron, Louise M Clark, Brittaney Leeper, Quang-De Nguyen, Berkley E Gryder, Mariella G Filbin, Jun Qi
Förderung
- Pediatric Brain Tumor Foundation
- Musella Foundation for Brain Tumor Research & Information Inc.
- ChadTough Defeat DIPG Foundation
- The Cure Starts Now
- Andruzzi Foundation
- Alex's Lemonade Stand Foundation
- Solving Kids' Cancer, Inc.
- The Bibi Fund
Zitieren
APA
Groves, A., Kirkland, O. O., Lo Cascio, C., Wang, X., Heaslip, C., Graca Marques, J., Song, C., Poetschke, R., Wang, T., Chin, D. H., Asante, Y., Liu, Q., Kim, H., Gu, S., Trissal, M., Labelle, J., Veiga Cruzeiro, G. A., Jones, K. L., Cameron, A. B., …, & Qi, J. (2026). Selective histone deacetylase inhibition as a therapeutically relevant strategy in H3K27M-glioma. Neuro-Oncology. https://doi.org/10.1093/neuonc/noag142
Vancouver
Groves A, Kirkland OO, Lo Cascio C, Wang X, Heaslip C, Graca Marques J, et al. Selective histone deacetylase inhibition as a therapeutically relevant strategy in H3K27M-glioma. Neuro-Oncology. 2026. doi:10.1093/neuonc/noag142
BibTeX
@article{Groves2026,
author = {Groves, Andrew and Kirkland, Orville O and Lo Cascio, Costanza and Wang, Xiuqi and Heaslip, Caleb and Graca Marques, Joana and Song, Chen and Poetschke, Rebecca and Wang, Tingjian and Chin, Diana H and Asante, Yaw and Liu, Qi and Kim, Hyunmin and Gu, Shanqing and Trissal, Maria and Labelle, Jenna and Veiga Cruzeiro, Gustavo Alencastro and Jones, Kristen L and Cameron, Amy B and Clark, Louise M and Leeper, Brittaney and Nguyen, Quang-De and Gryder, Berkley E and Filbin, Mariella G and Qi, Jun},
title = {Selective histone deacetylase inhibition as a therapeutically relevant strategy in H3K27M-glioma},
journal = {Neuro-Oncology},
year = {2026},
doi = {10.1093/neuonc/noag142}
}
EUVIMED